Septerna (SEPN) had its "buy" rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.
Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism
Septerna (SEPN) had its price target raised by JPMorgan Chase & Co. from $34.00 to $38.00. They now have an "overweight" rating on the stock.
Septerna (SEPN) had its price target raised by Truist Financial Corporation from $34.00 to $35.00. They now have a "buy" rating on the stock.